Sleep as a Novel Biomarker and a Promising Therapeutic Target for Cerebral Small Vessel Disease: A Review Focusing on Alzheimer’s Disease and the Blood-Brain Barrier

dc.bibliographicCitation.firstPage6293eng
dc.bibliographicCitation.issue17eng
dc.bibliographicCitation.journalTitleInternational journal of molecular scienceseng
dc.bibliographicCitation.volume21eng
dc.contributor.authorSemyachkina-Glushkovskaya, Oxana
dc.contributor.authorPostnov, Dmitry
dc.contributor.authorPenzel, Thomas
dc.contributor.authorKurths, Jürgen
dc.date.accessioned2021-11-08T07:34:44Z
dc.date.available2021-11-08T07:34:44Z
dc.date.issued2020
dc.description.abstractCerebral small vessel disease (CSVD) is a leading cause of cognitive decline in elderly people and development of Alzheimer’s disease (AD). Blood–brain barrier (BBB) leakage is a key pathophysiological mechanism of amyloidal CSVD. Sleep plays a crucial role in keeping health of the central nervous system and in resistance to CSVD. The deficit of sleep contributes to accumulation of metabolites and toxins such as beta-amyloid in the brain and can lead to BBB disruption. Currently, sleep is considered as an important informative platform for diagnosis and therapy of AD. However, there are no effective methods for extracting of diagnostic information from sleep characteristics. In this review, we show strong evidence that slow wave activity (SWA) (0–0.5 Hz) during deep sleep reflects glymphatic pathology, the BBB leakage and memory deficit in AD. We also discuss that diagnostic and therapeutic targeting of SWA in AD might lead to be a novel era in effective therapy of AD. Moreover, we demonstrate that SWA can be pioneering non-invasive and bed–side technology for express diagnosis of the BBB permeability. Finally, we review the novel data about the methods of detection and enhancement of SWA that can be biomarker and a promising therapy of amyloidal CSVD and CSVD associated with the BBB disorders. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.eng
dc.description.versionpublishedVersioneng
dc.identifier.urihttps://oa.tib.eu/renate/handle/123456789/7197
dc.identifier.urihttps://doi.org/10.34657/6244
dc.language.isoengeng
dc.publisherBasel : Molecular Diversity Preservation Internationaleng
dc.relation.doihttps://doi.org/10.3390/ijms21176293
dc.relation.essn1422-0067
dc.rights.licenseCC BY 4.0 Unportedeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/eng
dc.subject.ddc570eng
dc.subject.ddc540eng
dc.subject.otherAlzheimer’S diseaseeng
dc.subject.otherBlood-brain barriereng
dc.subject.otherCerebral small vessel diseaseeng
dc.subject.otherSleepeng
dc.subject.otherSlow wave activityeng
dc.titleSleep as a Novel Biomarker and a Promising Therapeutic Target for Cerebral Small Vessel Disease: A Review Focusing on Alzheimer’s Disease and the Blood-Brain Barriereng
dc.typeArticleeng
dc.typeTexteng
tib.accessRightsopenAccesseng
wgl.contributorPIKeng
wgl.subjectBiowissensschaften/Biologieeng
wgl.typeZeitschriftenartikeleng
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Sleep as a novel biomarker and a promising therapeutic target for cerebral small vessel disease_A review focusing on alzheimer’s disease and the blood-brain barrier.pdf
Size:
3.79 MB
Format:
Adobe Portable Document Format
Description: